Latest Breaking News On - Presented today - Page 1 : comparemela.com

egnite, Inc and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

egnite, Inc and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Aliso viejoUnited statesTorrey loperMarissa bychPeijia medicalQatar investment authorityJenavalve technology incBain capital life sciencesValiance life sciencesCompany trilogyStudy ledPresented todayKey findings demonstrate untreated mortality riskSome patientsModerate aortic regurgitationCardiac damage

egnite, Inc and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

egnite, Inc and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAliso viejoTorrey loperMarissa bychPeijia medicalQatar investment authorityBain capital life sciencesJenavalve technology incCompany trilogyValiance life sciencesPresented todayFindings demonstrate untreated mortality riskSome patientsModerate aortic regurgitationCardiac damageSevere aortic regurgitation

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United arab emiratesUnited statesUnited kingdomNew jerseyGreat britainClin cardiolColl cardiolMark marmurExchange commissionAmarin corporationDrug administrationEuropean unionA report from the american heart associationAmerican heart associationAnalyses showRelative risk reduction compared

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesUnited arab emiratesNew jerseyGreat britainMark marmurColl cardiolClin cardiolAmerican heart associationAmarin corporationEuropean unionA report from the american heart associationDrug administrationExchange commissionAlso foundTotal events compared

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative

Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo

United kingdomUnited statesNew jerseyUnited arab emiratesGreat britainMark marmurClin cardiolColl cardiolA report from the american heart associationEuropean unionDrug administrationAmerican heart associationAmarin corporationExchange commissionAlso foundTotal events compared